Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast. Sales of Lilly’s ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Hims’ Super Bowl ad is optimized to infuriate ... It’s an obvious knock at expensive GLP-1 drugs like Wegovy and Zepbound. Hims, of course, sees itself as the solution to the problem, and ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing ... for such products as Alzheimer's disease (AD) treatment Kisunla, ulcerative colitis ...